biostudies-literatureUnknown8(3)Lagneaux E<h4>Background</h4>Venous malformations (VMs) are commonly associated with localized intravascular coagulopathy leading to elevated D-dimer and risks of hemorrhagic and thromboembolic events, particularly in extensive lesions. While low-molecular-weight heparin (LMWH) has been effective in managing coagulopathy and pain, direct oral anticoagulants (DOACs) emerge as a promising alternative.<h4>Objectives</h4>This study aims to evaluate the efficacy and safety of DOACs in treating VMs associated with localized intravascular coagulopathy, offering a comparative perspective to LMWH.<h4>Methods</h4>A retrospective study was conducted on 29 patients with VMs and secondary localized intravascular coagulopathy treated with DOACs between 2013 and 2023 in a single tertiary center specialized in vascResearch and practice in thrombosis and haemostasis102400https://www.ebi.ac.uk/biostudies/studies/S-EPMC11087699biostudies-literatureDirect oral anticoagulants and venous malformations: literature review and retrospective study of 29 patients.PMC11087699Boon LMHermans CLagneaux EVikkula MRevencu NfalseDirect oral anticoagulants and venous malformations: literature review and retrospective study of 29 patients.<h4>Background</h4>Venous malformations (VMs) are commonly associated with localized intravascular coagulopathy leading to elevated D-dimer and risks of hemorrhagic and thromboembolic events, particularly in extensive lesions. While low-molecular-weight heparin (LMWH) has been effective in managing coagulopathy and pain, direct oral anticoagulants (DOACs) emerge as a promising alternative.<h4>Objectives</h4>This study aims to evaluate the efficacy and safety of DOACs in treating VMs associated with localized intravascular coagulopathy, offering a comparative perspective to LMWH.<h4>Methods</h4>A retrospective study was conducted on 29 patients with VMs and secondary localized intravascular coagulopathy treated with DOACs between 2013 and 2023 in a single tertiary center specialized in vasc2024-01-01T00:00:00Z2024 Mar2026-06-02T11:33:12.336Z2026-05-27T03:12:00.963ZS-EPMC110876993873817210.1016/j.rpth.2024.102400